Bataille R, Morlock G, Rosenberg F, Lopitaux R, Blotman F, Sany J, Ciurana A J, Rampon S, Bussière J L, Simon L, Serre H
Rev Rhum Mal Osteoartic. 1980 Feb;47(2):77-82.
In order to study the response of patients with multiple myeloma of the bones (MM) to various anti-cancer drugs (Melphalan M, Cyclophosphamide Cy, Nitrosourea NU, Vincristine V, Adriamycine A and Prednisone P), 70 MM received the following treatment : 1) Induction therapy : a) M and P or b) M and Cy and P ; 2) Levelling with partial or complete response : V Cy P (in case a) or V M Cy P (in case b) ; 3) Relapse : A and NU. The following results were obtained : 1) Only 42.6% of patients respond to induction therapy ; 2) Fewer than 10% of patients showing a response reach a second levelling with Vincristine ; 3) 50% of those not showing a response reach a levelling between --20 and --50 and have prolonged survival ; 4) Only 20% of non responders are improved by Cy P or A and NU. The median actuarial survival is 42 months. Among the responders two poor prognosis factors must be underlined : hypercalcemia and the speed of response.
为了研究骨多发性骨髓瘤（MM）患者对各种抗癌药物（美法仑M、环磷酰胺Cy、亚硝基脲NU、长春新碱V、阿霉素A和泼尼松P）的反应，70例MM患者接受了以下治疗：1）诱导治疗：a）M和P，或b）M、Cy和P；2）达到部分或完全缓解后的巩固治疗：V、Cy、P（情况a）或V、M、Cy、P（情况b）；3）复发：A和NU。得到了以下结果：1）只有42.6%的患者对诱导治疗有反应；2）显示有反应的患者中，不到10%通过长春新碱达到第二次巩固治疗；3）50%无反应的患者达到-20至-50之间的巩固治疗并延长了生存期；4）只有20%的无反应者通过Cy、P或A和NU得到改善。中位精算生存期为42个月。在有反应者中，必须强调两个预后不良因素：高钙血症和反应速度。
